

Januar 18th, 2023

Europe | Germany

DR. KALLIWODA

RESEARCH GmbH

DR. KALLIWODA Products

DR. KALLIWODA RESEARCH in bullets:

Research

- Over 1400 Research Reports since 2003
- Huge Distribution List of over 6000 Institutional Investors
- Bloomberg & Reuters Distribution Licence

Roadshows

- Over 550 Roadshows performed.
- Over 50 Conferences in Europe performed
- Outside DACH-REGION: Strongest Investors Base in Spain, France, Poland and Belgium and Netherlands

Conferences

- Big Experiences in Venture and Private Equity Companies.
- Very qualified Analyst Team, CFA, CEFA/DVFA certified.
- Strong focus of smallcaps but also of BigCaps


Sustainability Research

- Over 100 research investigation

CEO

Dr. Norbert Kalliwoda
nk@kalliwoda.com
Tel.:0049-69-97205853
Bloomberg: KALL

Where have we performed our roadshows



A) Dr. Kalliwoda Capital Markets Conferences 2024:

26.01.2024	London		3	. Conference in London
06.02.2024	Warsaw		22	. Conference in Warsaw
07.02.2024	Warsaw		22	. Conference in Warsaw
08.02.2024	Warsaw	online	22	. Conference in Warsaw
09.02.2024	Warsaw	online	22	. Conference in Warsaw
18.04.2024	Brussels		13	. Conference in Brussels
19.04.2024	Amsterdam		13	. Conference in Amsterdam
23.05.2024	Madrid	online	16	. Conference in Madrid
24.05.2024	Madrid		16	. Conference in Madrid
27.05.2024	Barcelona		16	. Conference in Barcelona
04.06.2024	Warsaw		23	. Conference in Warsaw
05.06.2024	Warsaw		23	. Conference in Warsaw
06.06.2024	Warsaw	online	23	. Conference in Warsaw
07.06.2024	Warsaw	online	23	. Conference in Warsaw
06.09.2024	Madrid	online	17	. Conference in Madrid
05.09.2024	Madrid		17	. Conference in Madrid
06.09.2024	Barcelona		17	. Conference in Barcelona
12.09.2024	London		4	. Conference in London
13.09.2024	London	online	4	. Conference in London
25.10.2024	New York	online *)	3	. Roadshow in New York
28.10.2024	New York	online *)	3	. Roadshow in New York
06.11.2024	Shanghai	online *)	4	. Roadshow in Shanghai
07.11.2024	Hongkong	online *)	4	. Roadshow in Hongkong
11.11.2024	Singapur	online *)	4	. Roadshow in Singapur
12.11.2024	Singapur	online *)	4	. Roadshow in Singapur
26.11.2024	Zurich		8	. Conference in Zurich
27.11.2024	Lugano		8	. Conference in Lugano
28.11.2024	Lugano	online	8	. Conference in Lugano
06.12.2024	Frankfurt		8	. Conference in Frankfurt/M.
10.12.2024	Paris	online	9	. Conference in Paris
11.12.2024	Paris		9	. Conference in Paris
12.12.2024	Geneva		9	. Conference in Geneva
13.12.2024	Nizza		9	. Conference in Nizza

*) On site on request

B) Dr. Kalliwoda Capital Evenings (Single Equities):

17.01.2024	Frankfurt/M.		26	. Capital Evening in Westendoffice
15.03.2024	Frankfurt/M.		27	. Capital Evening in Westendoffice
10.05.2024	Frankfurt/M.		28	. Capital Evening in Westendoffice

C) Dr. Kalliwoda Capital Evenings (Investmentfonds):

21.06.2024	Frankfurt/M.	25	Capital Evening in Westendoffice
23.08.2024	Frankfurt/M.	26	Capital Evening in Westendoffice
18.10.2024	Frankfurt/M.	27	Capital Evening in Westendoffice

D) Dr. Kalliwoda Roadshows:

- Oslo
- Stockholm

We are also happy to run an investor roadshow with you outside of Europe through in:

- Copenhagen
- Lisbon & Porto
- London
- Paris
- Vienna
- Luxembourg
- Vaduz/Liechtenstein

- New York
- Singapor
- Hongkong
- Shanghai

E) Register your compulsory analyst event through us:

Basis: Exchange Rules for the Frankfurt Stock Exchange (BörsO FWB).

We can, of course, organise your annual compulsory event for you in accordance with the Exchange Rules (BörsO FWB) and hold it at a location of your choice or at our Westend Office.

After more than 23 years of activity, we have first-class contacts to investors, whom we invite to your compulsory event.

On the part of both investors (asset owners) and investor-seeking companies we were able to hold traditional on-site conferences and digital conferences.

Although this digital form did not create the personal contact on site, but the digital form nevertheless made it possible to see each other efficiently and to continue an intensive dialogue. In most cases, even more institutional investors could be reached digitally even more institutional investors than is the case with our traditional conferences. We will certainly offer you both forms as an option in the future.

Therefore, you should already choose the dates and locations of our conferences and capital events and roadshows that fit your annual schedule.

Please send an e-mail to: research@kalliwoda.com or nk@kalliwoda.com
 or call us: **0049 69-97 20 58 53** or mobile no. **0049 172 6190796** or **0049 152 53565081**.
 We look forward to your feedback and thank you for the cooperation so far and in the future.



Seit/since 2003

Dr. Norbert Kalliwoda,
 geschäftsführender Gesellschafter,
 Managing Owner, Dipl.-Kfm., CEFA-Analyst

Arndtstraße 47, D-60325 Frankfurt am Main
 Tel.: +49 69 97 20 58 53
<http://www.kalliwoda.com>

<https://www.linkedin.com/company/kalliwoda-research>
https://twitter.com/drkalliwoda_r

E-Mail: research@kalliwoda.com
 E-Mail: nk@kalliwoda.com

REFERENCES about our Conferences, Roadshows and Research:

- [26. ESSILORLUXOTTICA SA Referenz](#)
- [25. CEWE Stiftung & Co. KGaA Referenz](#)
- [24. VOLKSWAGEN AG Referenz \(engl.\)](#)
- [23. Deutsche Beteiligungs AG Referenz](#)
- [22. CLIQ Digital AG Referenz \(engl.\)](#)
- [21. mVISE AG Referenz \(engl.\)](#)
- [20. Fabasoft AG Referenz \(engl.\)](#)
- [19. Metzler Bank KGaG Referenz](#)
- [18. BB BIOTECH AG Referenz](#)
- [17. bet-at-home.com AG Referenz](#)
- [16. Kromi Logistik AG Referenz \(engl.\)](#)
- [15. Skagen Funds Referenz \(engl.\)](#)
- [14. Deutsche Rohstoff AG Referenz](#)
- [13. Zalando SE Referenz](#)
- [12. PSI Software AG](#)
- [11. Hamborner Reit AG](#)
- [10 Jungheinrich AG Referenz \(engl.\)](#)
- [9 Formycon AG Referenz](#)
- [8 Gesco AG Referenz](#)
- [7 United Internet AG Referenz \(engl.\)](#)
- [6 Ahlers AG Referenz](#)
- [5 Jenoptik AG Referenz \(engl.\)](#)
- [4 Talanx AG Referenz \(engl.\)](#)
- [3 ElringKlinger AG Referenz](#)
- [2 Fielmann AG Referenz](#)
- [1 Telekom Austria AG Referenz](#)

DR. KALLIWODA RESEARCH, FRANKFURT



Skyline Frankfurt am Main



Dr. Norbert Kalliwoda, CEO



Dr. Kalliwoda Research Office in Frankfurt



Photography © 2023: Dr. Kalliwoda Research GmbH

DR. KALLIWODA RESEARCH, WARSAW

DR. KALLIWODA RESEARCH, WARSAW



Palace of Culture and Science



Our Conference in Warsaw/Team-member.



Dr. Kalliwoda Team Warsaw



Warsaw City, Palace of Culture

Photography © 2023: Dr. Kalliwoda Research GmbH

DR. KALLIWODA RESEARCH, MADRID




Madrid



Team-Mitglied in Madrid




Dr. Kalliwoda Team Madrid



Madrid

Fotografien © 2023: Dr. Kalliwoda Research GmbH

Contacts

Primary Research Fair Value Analysis International Roadshows		Dr. Kalliwoda Research GmbH, www.kalliwoda.com Steinstraße 24, D-64839 Münster, office Frankfurt Arndtstr. 47, 60325 Frankfurt, Tel.: 069-97 20 58 53; Fax: 069-13 81 92 15
Head: Dr. Norbert Kalliwoda E-Mail: nk@kalliwoda.com	CEFA-Analyst; University of Frankfurt/Main; PhD in Economics; Dipl.-Kfm., Dipl.-Hdl.	<u>Sectors:</u> IT, Software, Electricals & Electronics, Mechanical Engineering, Logistics, Laser, Technology, Raw Materials
Lukas Ankelmann E-Mail: la@kalliwoda.com	Junior-Analyst; University Nuremberg	<u>Sectors:</u> Technology, New Media, Food & Beverage
Dr. Peter Arendarski E-Mail: pa@kalliwoda.com	Senior-Analyst, Msc & Ph. D in Finance (Poznan Univers. of Econ.), CFA; lev 3	<u>Sectors:</u> Technology, Raw Materials, Banks & Insurances, Financial-Modelling (Quant., Buyside)
Noah Barnekow E-Mail: nb@kalliwoda.com	Junior Analyst (Frankfurt School of Finance & Management)	<u>Sectors:</u> Aviation, Automotive, Technology, Sustainability Approach
Leander Grub E-Mail: lg@kalliwoda.com	Junior-Analyst (University Rotterdam)	<u>Sectors:</u> eSports, Gaming, Consumer, Retail, Fashion
Michael John E-Mail: mj@kalliwoda.com	Dipl.-Ing. (Aachen)	<u>Sectors:</u> Chemicals, Chemical Engineering, Basic Metals, Renewable Energies, Laser/Physics
Witold Konrad Kosinski E-Mail: wk@kalliwoda.com	Finance & Banking Warsaw School of Econ, Master of Science; postgrad. Managem	<u>Sectors:</u> Consumer Goods, Trading Companies, Food & Beverages, Technology
Sebastian Krawczyk E-Mail: sk@kalliwoda.com	Bachelor Management, Quant. Meth. in Economics & Inf. Systems Warsaw School	<u>Sectors:</u> Quantitative Methods, Automotive, Technology
Martin Kostovski E-Mail: mko@kalliwoda.com	Analyst (Frankfurt School of Finance and Managem., BSc. focus on Bank. & Finan.)	<u>Sectors:</u> Software, Commodities
Vittoria Lou D. Mawis E-Mail: cl@kalliwoda.com	Architect; University Barcelona	<u>Sectors:</u> Assistant Office, Real Estate
Dr. Heinz Müller E-Mail: hm@kalliwoda.com	Dr. agr, Dipl.-agr. (Agrarökonomie)	<u>Sectors:</u> Agrochemicals, Consumer Chemicals, Chemicals
Dr. Christoph Piechaczek E-Mail: cp@kalliwoda.com	Dipl.-Biologist; Technical University Darmstadt; Univ. Witten-Herdecke.	<u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical
Nele Rave E-Mail: nr@kalliwoda.com	Lawyer; Native Speaker, German School London,	<u>Legal adviser</u>
Isidor Rosenthal E-Mail: ir@kalliwoda.com	Analyst (Frankfurt School of Finance and Management, BSc. (Banking and Finance)	<u>Sectors:</u> MedTec, Pharma, Consumer-Staples, Defense
Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com	Dipl.-Geophysicists; University of Frankfurt/Main.	<u>Sectors:</u> Oil, Regenerative Energies, Specialities Chemicals, Utilities
Dr. Erik Schneider E-Mail: es@kalliwoda.com	Dipl.-Biologist; Technical University Darmstadt; Univ. Hamburg.	<u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical
Leonard Schüppler E-Mail: ls@kalliwoda.com	Junior-Analyst; WHU - Otto Beish. School of Management Vallendar	<u>Sectors:</u> Luxury Goods, Consumers, digital businesses
Hans-Georg Sutter E-Mail: hsu@kalliwoda.com	Dipl.-Wirtschaftsingenieur University Kaiserslautern	<u>Sectors:</u> IT/e-commerce
Lukas Thiele E-Mail: lt@kalliwoda.com	Analyst (Bachelor Business Administr. Univers. Frankfurt am Main)	<u>Sectors:</u> Automotive, Technology, IT
Liudmila Trifonova E-Mail: ltr@kalliwoda.com	Analyst (Johannes Gutenberg-Universität Mainz (Business & Economics)	<u>Sectors:</u> Media, Videogames, Sustainability
<p>Also view Sales and Earnings Estimates:</p> <p>DR. KALLIWODA RESEARCH on Terminals of Bloomberg <u>Page KALL</u>, Thomson Reuters, vwd group and Factset</p>	CEO: Dr. Norbert Kalliwoda, CEFA	

Disclaimer

Essential information, disclosures and disclaimer

A. Essential information

The investments in financial instruments and securities (e.g. equities, bonds) generally involved on high risks. It is possible that the investors lose some or all of the invested money. Potential investors should be aware of the fact that the prices of securities could fall and rise. The income from such an investment might be considerable fluctuations. Investment strategies are not appropriate at all times and past results are not a guarantee for the future performance. Investors should make their own and independent decisions as to whether a risky investment.

B. Disclosures according to Section 34b of the German Securities Trading Act (WpHG) and to the German Regulation governing the Analysis of Financial Instruments (FinAnV).

I. Information about author, company held accountable, regulatory authority:

Company responsible for the content of this document: DR. KALLIWODA RESEARCH GmbH, Frankfurt am Main, Germany.

Regulatory authority for DR. KALLIWODA RESEARCH GmbH is the Federal Financial Supervisory Authority (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany and Lurgiallee 12, 60439 Frankfurt am Main, Germany.

Author of this research: Dr. Norbert Kalliwoda, Analyst, CEO and founder of DR. KALLIWODA RESEARCH GmbH.

II. Additional Information:

1. Sources of information:

Essential sources of information for the compilation of this document are publications from domestic and international information services and media (e.g. Bloomberg, dpa-AFX, Reuters, VWD, among others), financial press (e.g. *Allgemeine Zeitung Frankfurter*, *Börsenzeitung*, *Financial Times Handelsblatt* and others), specialized trade press, published statistics, rating agencies as well as publications by peer group companies and the company itself. Additionally, conservation has been held with the management of the company. This document was made available to the company before publishing to ensure the correctness of the information provided.

2. Summary of the basis of valuation principles and methods used to prepare this document:

Within the scope of the evaluation of companies the following valuation methods are applied: Multiple-based models (Price/Earnings, Price/Cash-flow, Price/Book value, EV/Sales, EV/EBIT, EV/EBITDA), peer group comparisons, historic valuation methods, discounting models, sum-of-the-parts-approaches, substance-valuation methods and swot-analyses. The valuation principles and models are dependent on macroeconomic factors, such as interest rates, exchange rates, raw materials and on basic assumptions about the economy. Besides, the market moods and market sentiment affects the valuation of enterprises. The approaches are based on expectations that could change rapidly and without advance warning according on developments specific to individual branch. The valuation results and fair values derived from the models might therefore change accordingly.

The ratings are the evaluation results and refer to a fair value pricing reflecting a time-horizon of up general relate to a twelve-months. Nevertheless, evaluation results are subject to changing market conditions and constitute merely

a snapshot. The evaluation results and fair values may be reached faster or slower than expected by the analysts. The results and fair values may to be scale upwards or downwards.

DR. KALLIWODA RESEARCH GmbH uses the following rating model:

BUY:	Based on our analysis, we expect the stock to appreciate and produce a total return of at least 10% over the next twelve months
ACCUMULATE:	Based on our analysis, we expect the stock to appreciate and produce a total return between 5%- 10% over the next twelve months
HOLD:	Based on our analysis, we expect the stock to produce a total return between -5% and +5% over the next twelve months
REDUCE:	Based on our analysis, we expect the stock to cause a negative return between -5% and -10% over the next twelve months
SELL:	Based on our analysis, we expect the stock to cause a negative return exceeding -10% over the next twelve months

3. Date of first publication of this document: December 19th 2022

4. Updates:

A specific update of this document has currently not been set. The research reflects the author's judgement on the date of this publication and is subject to change without any notice. The document might be incomplete or reduced and it may not contain all information concerning the company covered. It is in the sole decision of DR. KALLIWODA RESEARCH GmbH whether and when a potential update of this research is made.

III. Disclosures about potential conflicts of interest:

The business model of DR. KALLIWODA RESEARCH GmbH is based on economic relationships with issuer company and equity transactions to be performed relating to the issuer's stock. Dr. Kalliwoda Research has entered into an agreement about the creation of this document with the company which is, or whose financial instruments are the issue of this research.

Conflicts of interest may be in existence with employees of DR. KALLIWODA| RESEARCH GmbH who are the authors of this document as well as other persons that were involved in the preparation of this research or related parties.

Following conflicts of interest might exist:

- DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have a major shareholding (holding more than 5%) of the share capital of the emitter that is, or whose financial instruments are, the subject of the research.**
 - DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties are possibly holders of instruments that are mentioned in this research (or that are linked to these instruments) or might become holders and could regularly trade the emitter's securities or securities based on these issues as principal or agent.**
 - DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties could have participated in leading a consortium for the emitter via a public offering of the financial instruments that are the subject of this research.**
-

4. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have been party to an agreement on the provision of investment banking services with the issuer which is the subject of this research, or have received services or a pledge to perform under the terms of such an arrangement during the same period.
5. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties may have other substantial economic interests concerning to the issuer which is the subject of this research.
6. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have been party to an agreement with the company, which is the subject of this research, resulting in receiving the compensation for preparation of this research.
7. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties received the feedback concerning the company profile and SWOT from the company, which is the subject of this research, before publishing this report to the public.

Important: Please get familiar with possible risks and possible conflicts of interest in the disclosure and disclaimer at the end of this report, especially for this report: 6. and 7.

The analysts have limited access to gain information that possibly could constitute a conflict of interest for the institution DR. KALLIWODA RESEARCH GmbH keeps insider registers appropriate to sec. 15 WpHG for assignees that normally have approach to inside information. Insiders' dealings appropriate to sec. 14 WpHG categorically are prohibited.

The analysts that composed this research did not receive or acquire shares in the issuer that is the subject of this document at any time. The analysts mentioned above hereby certify that all of the views expressed accurately reflect the individual views about the issuer. No part of the indemnity was, is or will be, directly or indirectly, linked to the evaluation result or views expressed by the analyst in this research.

C. Disclaimer:

This document is published and being distributed by DR. KALLIWODA RESEARCH GmbH solely for informational purposes and for the personal use by persons in Germany. This research is not intended to be in any form an offer or advice to buy or sell the securities referred to herein. This research is intended to provide information to assist investors in making their own investment decisions. Any decision to purchase any securities of the issuer must be made solely on the basis of the information contained in the offering documents from the issuer relating to such securities and not on the contents hereof. Furthermore, our recommendation may not be fully suitable to every investor, depending on their investment objective, individual financial situation or targeted holding period.

Potential investors should seek professional and individual information and advice before making their investment decisions. This document neither constitutes a contract or any kind of obligation.

Neither this document nor any copy, in whole or in part, thereof may be distributed in any other jurisdiction where its distribution might be restricted by law, and person into whose published this document comes should inform and observe themselves about any such restrictions.

The information within this document has been obtained from sources believed by DR. KALLIWODA RESEARCH GmbH to be reliable. DR. KALLIWODA RESEARCH GmbH does not examine the information to be verify and complete, nor warrants its correctness and completeness. Although due attention has been taken in compilation this document, it cannot be excluded that the information given is not complete or the document contains mistakes.

The liability of DR. KALLIWODA RESEARCH GmbH shall be restricted to gross negligence and wilful misconduct. All aspects penned in this document are those of DR. KALLIWODA RESEARCH GmbH respectively the authors and subject to modify without notice. Possible faults or incompleteness of this document may be

reformed by DR. KALLIWODA RESEARCH GmbH and do not constitute reasons for liability, neither with regard to indirect nor to direct or consequential losses.

Moreover, DR. KALLIWODA RESEARCH GmbH does not accept any responsibility and liability for any damage arising from using of this research or its contents or otherwise arising in relation herewith. In each case, the liability and responsibility of DR. KALLIWODA RESEARCH GmbH is limited to typical, predictable damages and the liability for any direct or indirect losses is excluded.

This document is subject to the laws of the Federal Republic of Germany. Place of jurisdiction is Frankfurt am Main, Germany.

This document or any copy, in whole or in part thereof, may be distributed in any other jurisdiction where its distribution might be restricted by law and persons who have access to this document have to inform and observe themselves about any such restrictions.

In the United Kingdom this document is to be distributed only to persons who are described in Section 11 (3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996 (as amended). This research may not be distributed and forwarded directly or indirectly to any other group of individuals. The distribution of this document in other international jurisdictions may be restricted by law and individuals who possess this study should inform themselves of any existing restrictions and comply with them.

Neither this document nor any copy of it may be taken or transmitted into the United States of America, Canada, Japan or Australia or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia or to any resident thereof. Any Failure to comply with these restrictions may constitute a violation of United States, Canadian, Japanese or Australian securities laws or the law of any other jurisdiction.

By confirming this document, the reader or user agrees and accepts to be bound by all of the foregoing provisions and this disclaimer. Besides, the user accepts not to distribute this document to unauthorized persons. The user of this document compensated DR. KALLIWODA RESEARCH GmbH for any disadvantages, damages, claims and losses resulting from or in relation with the unauthorized use of this document.

© 2022 DR. KALLIWODA RESEARCH GmbH, Arndtstraße 47, D-60325 Frankfurt am Main. All rights reserved.